You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 630 EO2401, a new peptide immunotherapy against cancer, in combination with nivolumab, induces a strong and durable immune response in patients from the EOADR1–19/SPENCER study

Citation Tools

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
630 EO2401, a new peptide immunotherapy against cancer, in combination with nivolumab, induces a strong and durable immune response in patients from the EOADR1–19/SPENCER study

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Aubergeon L, Baudin E, Berruti A, et al
630 EO2401, a new peptide immunotherapy against cancer, in combination with nivolumab, induces a strong and durable immune response in patients from the EOADR1–19/SPENCER study
Journal for ImmunoTherapy of Cancer 2023;11:doi: 10.1136/jitc-2023-SITC2023.0630